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Abstract: Synthesis of a new fluorinated nucleoside of 6,7-difluoro-2-methyl-4-quinazolinone was described. 2-Amino-4,5-difluorobenzoic
acid 1 reacts with (CH3CO)2O followed by ammonia to form (1H)-6,7-difluoro-2-methyl-4-quinazolinone 3a. Ribosylation of a silylated
4 with l-O-acety1-2,3-5-tri-O-benzoyl-α-D-ribofuranose 5 forms a protected nucleoside 6 then unprotected from 6 to give a free
nucleoside 7. Greener pasture biological docking of the cystine protease of COVID-19 [Mpro, code 7BQY, PDB] by novel nucleoside and
fluoroquinazoline compounds is presented. LIGPLOT (2D) representations calculated for the same ligands are shown. A superposition
of remdesivir approved medicine, N3 inhibitor, and our ligands docked together into the binding protein of 7BQY is also given for a fair
comparison. The binding affinities of remdesivir, N3 inhibitor, the nucleoside 7, and fluoroquinazoline 3a, 3b compounds with 7BQY
calculated under the same conditions are –7.7, –7.4, –7.6, –6.1, and –6.1 kcal mol–1, respectively. The high values were due to the existence
of many hydrophobic interactions and hydrogen bonds between the ligands and the active amino acid residues of the receptor, indicating
a promising candidate as a COVID-19 inhibitor. Pro Tox -II server showed that compound 7 has a similar feature to the approved antiviral
drug remdesivir for COVID-19. Additionally, a fascinating molecular modeling investigation showed that our nucleoside demonstrated
good binding inhibition of AChE enzyme towards advancing an efficient medication against Alzheimer’s disease. Finally, DFT has been
conducted to illustrate the MD results in terms of the molecular descriptor-based structural activity relationship calculated from FMOs.
Key words: Main protease, in silico, MD-DFT assessment, Alzheimer’s disease (AD), 6,7-difluoro-2-Methyl-4-quinazolinone

1. Introduction
4-quinazolinones are solids and stable to alkaline treatment and mild acid. The most common approach to synthesizing
4(3H)-quinazolinone products is the direct reaction of 2-aminobenzoic acid (anthranilic acid) derivatives with acetic
anhydride to give the benzoxazinone, followed by condensation with nitrogen nucleophiles [1–4]. The 2-methyl group
in 3H or 1H-4-quinazolinone is more responsive than 4-quinazoline. In general, quinazolinones have several biological
applications such as preventing cancer [2,5,6], anti-HIV [7], cytotoxicity in vitro [8], antiinflammatory [6,9], antibacterial
[10,11], antifungal [12], and antiviral properties [13,14]. Furthermore, the kinase inhibitory potency of many N-aryl
thiazolo[5,4-f]quinazolin-4-amines has been revealed, intending to improve the healing of Down syndrome (DS) and
early AD [15–18]. The fluorine atom is a significant substituent in medicinal chemistry due to its electronic properties
and improved molecular lipophilicity [19]. New fluorinated hydroquinazoline derivatives were used as antifungal agents
[20] and anticancer agents [21]. A difluorinated inhibitor showed 4.23 times larger potency against the epidermal growth
factor receptor (EGFR) than a nonfluorinated inhibitor [22]mutations of which have been linked specifically to nonsmallcell lung cancer. For the L858R/T790M/C797S triplet mutant (EGFRTM. In addition, quinazolinone nucleosides [23–26]
and fluorinated nucleosides have been used extensively in biological activity such as the prevention of cancer cells from
forming, anti-HCV activity in vitro [27], and anti-HBV agents [28].
* Correspondence: masaid@taibahu.edu.sa
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This article aims to report a new fluorinated nucleoside quinazolinone containing two fluorine atoms at positions 6
and 7 of the quinazolinone moiety [29]. When this compound was reacted with l-O-acety1-2,3-5-tri-O-benzoyl-β-Dribofuranose 5 by silated method [30], the fluorinated nucleoside; 6,7-difluoro 2-methylquinazolin-4-one 7 was obtained.
Also, given the current several ongoing concerns in medicine finding to monitor the horrific effect of the virus on our
daily lives [3,31–33], we have been encouraged to screen, in silico as a greener pasture preliminary step, the interaction
between our novel nucleoside: 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-6,7-difluoro-2-methyl-4-quinazolinone, 7 and
fluoroquinazoline, 3 ligands with the main protease (downloaded from RCSB, PDB) deposition code 7BQY) active site as
possible candidate drugs for COVID-19. It is worth mentioning here that nucleoside was tested before, in vitro, for antiviral
activity against two representative cowpox viruses, ortho poxviruses, and vaccinia virus [34]. We also investigated, in silco,
the molecular modeling of our nucleoside as a binding inhibition of AChE enzyme towards the advancement of an efficient
drug against Alzheimer’s disease.
2. Materials and methods
TLC was done using silica gel 60 (aluminum sheet, Fluka company) and revealed by UV-vis light. Melting points (mp) of
all synthesized compounds were determined using an electrothermal device and are uncorrected. The 1H and 13C NMR
spectra were measured on an NMR spectrometer in CDCl3, CD3OD at 213 and 850 MHz. Mass spectra were measured on
GC MS-QP 2000 EX mass spectrometer at 70 e.V (King Abdel Aziz University).
2.1. Synthesis
Synthesis of 6,7-difluoro-2-methylbenzo[2,3-d]oxazin-4-one (2)2-amino-4,5-difluorobenzoic acid 1 (1.6416 g,
0,009 mol) with a suitable quantity of acetic anhydride was refluxed for 1 h to reveal compound 2 as a brown powder.
Yield: 1.6971 g (89.5%); mp: 158 °C; molecular formula: C9H5NO2F2; molecular weight (mol. wt): 197.13.
Synthesis of 1H-6,7-difluoro-2-methyl-4-quinazolinone (3a)1.69 g (0.009 mol) of compound 2 with a suitable
quantitative amount of ammonia solution was refluxed for 6 h, cooled, and then treated with acetic acid to give crystals
collected by filtration as a white powder of compound 3a. Yield: 0.3690 g (21.95%); mp: 263–270 °C; molecular formula:
C9H6F2N2O, mol. wt: 196.15, MASS m/z (%): M+= 196.06 (100%), 196.04 (100%) [29,35].
Ribosylation of 1H-6,7-difluoro-2-methyl-4-quinazolinone:
1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-6,7-difluoro-2-methyl-4-quinazolinone (6)A mixture of 1H-6,7difluoro-2-methyl-4-quinazolinone 3a (0.369 g, 0.0018 mol), dry HMDS (20 mL) and a catalytic quantity of (NH4)2SO4
were heated under reflux for 24 h (TLC). The product was evaporated to dryness in anhydrous media to afford the
silylated derivative 4 as an intermediate compound, which added (10 mL) of dry 1,2-dichloroethane, (0.4694 g, 0.9 mmol)
1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (5) and (2 mL, 10 mmol) trimethylsilyl triflate; (TMSOTf as a catalyst).
The obtained solution was stirred for 14 days at room temperature and then washed with an aqueous NaHCO3 followed by
water and dried over sodium sulfate. The silica gel column chromatography with ethyl acetate and chloroform (2:98) was
used in order to separate the pure product. After evaporation, the main fraction 6 was obtained as a sticky yellow material.
Yield: 0.378 g (49.93%); mp: 180 °C; molecular formula: C35H26F2N2O8; mol. wt: 640.59; 1HNMR (CDCl3, 850 MHz, TMS),
δ H: 8.06–7.13 (m, 17H Aromatic protons), 6.0–6.1 (d, 1H, J = 4.25 Hz, H-1’), 5.62 (t, J = Hz,1H, H-2’), 4.97 (t, J = Hz,
1H, H-3’), 4.49–4.72 (m, 1H, H-5’), 4.01–4.06 (m, 1H, H-4’), 1.56 (s, 3H) CH3); 13CNMR (CD3OD, 213 MHz, TMS),
δ: 190.00, 167.63, 167.32, 164.32, 157.06, 155.73, 141.90, 138.05, 132.93, 132.87, 132.83, 130.57, 130.54, 129.71, 130.59,
129.92, 129.77, 129.74, 129.72, 129.50, 128.66, 128.43, 128.42, 128.40, 128.32, 128.29, 119.10; 117.75, 101.43, 79.16, 75.76,
70.25, 60.32, 65.14 CH2, 17.65 CH3.
Deprotection of 1-(2,3,5-tri-O-benzoyl-α-D-ribofuranosyl)-6,7-difluoro-2-methyl-4-quinazolinone-1-(α-Dribofuranosyl)-6,7-difluoro-2-methyl-4-quinazolinone (7).
A mixture of compound 6 (0.5 mmol), and sodium metal (0.001g) in methanol (dry, 10 mL), 0.04 mmol) was stirred
at room temperature for 1day. It was then treated with drops of acetic acid to neutralize the solution. The residue was
recrystallized from water to offer 7 as light-yellow crystals. Yield: 0.152 g (81.28%); mp: 255 °C; molecular formula:
C14H14F2N2O5, mol. wt: 328.27; 1HNMR (CD3OD, 850 MHz, TMS), δ: 7.88 (s, 1H, H-5’), 6.94 (s, 1H, H-8), 6.9 (d, 1H, J =
6.80 Hz, H-1’), 6.60–6.63 (m, 1H, H-2’), 5.65 (d, 1H, J = 4.25 Hz, OH2’), 5.33 (d, 1H, J = 1.7 Hz, OH3’), 5.18 (d, 1H, J = 3.4
Hz, OH5’), 4.70–4.95 (m, 3H, H-3’, OH-3’, OH-2’), 3.63–3.68 (m, 2H, H-4’, OH-4’), 3.52(t, J1 = 6.80, J2 = 6.80 Hz, 1H, H-5’),
1.88 (s, 3H, CH3); 13CNMR (CD3OD, 213 MHz, TMS), δ: 160.0, 129.3, 128.8, 128.2, 127.2, 127.1, 126.0, 124.0, 78.0, 61.6,
51.2, 51.0, 50.9, 29.3; MASS m/z (%): M+ = 327.21, 326.00, 322.24, 319.18 (100), 306.24, 301.10, 298.21, 293.98, 287.08,
279.07, 263.12, 260.05, 328.14, 252.20, 243.94, 232.96, 220.02, 203.96, 193.11, 190.90, 184.95, 171.95, 163.98, 155.16,
142.95, 123.99, 107.03, 102.90, 91.97. (calc. 328.27).
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2.2. Docking in silico studies
The molecular docking studies of our nucleoside compound and donepezil were done using the PyRx 0.8 (https://
sourceforge.net/projects/pyrx/). It is a recommended and powerful visualization engine [36]offering preprocessing and
postprocessing adapted (to date. The settings in the PyRx 0.8 include: Grid box (19.61, 29.01, 36.27 A˚), (3.54, 64.29, 64.01
A˚) centered at (19.61, 29.10, 26.27), (23.06, 25.0, 25.0) for 7BQY and 1ELE. Energy range = 4 and exhaustiveness = 8.
Water molecules and the N3 ligand were deleted from the proteases (PDB code 7BQY, 1EVE). The key residues of 7BQY
used in this study were identified before [31, 37].
2.3. Molecular descriptor-based structural activity relationship calculated from FMOs
The optimal architectural structures of the synthesized compounds 3a, 3b, and 7 were computed in the gas phase using
Gaussian 9 on the B3LYP 6-311G basis set and have been used in the calculation of the molecular chemical descriptors.
The energy levels of the frontier molecular orbitals highest occupied molecular orbitals (HOMOs) and lowest occupied
molecular orbitals (LUMOs) could be used to compute several chemical descriptors (least unoccupied molecular orbitals).
Furthermore, HOMOs and LUMOs in the examined compounds could be used as a qualitative predictor of their ability
to donate or receive electrons from the neighboring receptor [38–40]. FMOs, in general, are a powerful component
for obtaining realistic qualitative data on excitation qualities in a variety of chemical and pharmacological processes
[39,41–44]. Furthermore, FMO-derived chemical descriptors have been employed to estimate biological activities
[45–54]4-dihydro-[1,2,4]triazole-3-thione was synthesized and structurally characterized by elemental analysis, FT-IR,
Raman, 1H and 13C-NMR and UV–Vis studies. A density functional theory (DFT. Likewise, the FMOs energy levels and
the energy gaps may influence the kind and amount of binding during their interactions with receptors. As a result,
nonbonding intermolecular interactions such as hydrophilic interactions and H-bonding occur with the receptor.
Table 1 presents many estimated thermodynamic molecular descriptors, including dipole moment (µ), electronegativity
(χ), charge transfer prevention extent, global hardness (η), and electrophilicity (ω) determined from electronegativity and
chemical hardness values.
3. Results and discussion
Compounds 2–7 were prepared as displayed in Schemes 1 and 3. The structures of the newly synthesized organic
compounds were confirmed using 1H, 13C NMR, and mass spectra.
Benzoxazinone compounds can be prepared by treatment of anthranilic acid derivatives with acid chloride [1] or acetic
anhydride [2,55]5-dimethyl-2-thiazolyl. The 6,7-difluoro-4-benzoxazinone 2 was prepared from the reaction of 2-amino4,5-difluorobenoic acid 1 with acetic anhydride for 1 h. Treatment of compound 2 with ammonia solution for 6 h afforded
the (3H)-6,7-difluoro-2-methyl-4-quinazolinone 3, Scheme 1.
Weddige identified the tautomeric characteristics of (3H) 4-quinazolinones, which could exist in three tautomeric forms.
The existence of 4-hydroxy quinazoline was displayed by its stability in aqueous alkali at pH 12 to give the anion form. The
4-quinazolinones usually do not dissolve in alkali, mainly when a substitute is present on N1 or N3 [15]. The compound,
6,7-difluoro-2-methyl-4-quinazolinone is expected to have three tautomeric forms of (1H) 6,7-difluoro-2-methyl-4quinazolinone 3a, 3b, and 3c, Scheme 2.
Table 1. Dipole moment and chemical reactivity descriptors (Debye, µ) of the prepared compounds 3 and 7.
Parameter

3a

3b

7

LUMO

–2.17

–1.97

–2.23

HOMO

–6.96

–6.96

–6.96

ΔELUMO-HOMO

4.80

5.00

4.74

4.57

4.47

4.60

2.40

2.50

2.37

0.42

0.40

0.42

4.34

3.99

4.46

I=-EHOMO

6.96

6.96

6.96

A=-ELUMO

2.17

1.97

2.23

µ

4.87

5.87

6.87
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Scheme 1. Synthesis of nucleoside (3H)-6,7-difluoro-2-methyl-4-quinazolinone

Scheme 2. Tautomeric properties of (1H)-6,7-difluoro-2-methyl-4-quinazolinone 3a,3b, and 3c.

A mixture of 3a, dry HMDS, and a catalytic quantity of (NH4)2SO4 was heated under reflux for 24 h (TLC). The product was
evaporated to dryness in anhydrous media to afford the silylated derivative 4 as an intermediate compound. Compound 5
was treated with trimethylsilyl triflate; (TMSOTf as a catalyst), an aqueous NaHCO3, and silica gel column chromatography
with ethyl acetate and chloroform (2:98) to obtain 6 as a sticky yellow material. The 1H NMR of the protected nucleoside
6 shows a doublet signal at δ = 6.1 ppm allocated to the anomeric protons of the ribose moiety with a J coupling constant
equal to 4.25 Hz matches the 1’-proton. The spectra appeared as multiple signals of the configuration at δ = 8.06–7.13 ppm
due to benzoyl groups and quinazolinone protons in an aromatic region, see Scheme 3 and Figure 1.
Deprotection of the benzoyl group of protected nucleoside 6 was achieved in sodium metal in dry methanol at room
temperature for 24 h to give the corresponding free nucleoside 7. The 1H NMR of 7 showed the prospective base moiety
protons and the sugar moiety protons, though no signal for benzoyl protons appeared. Also, the 1H NMR spectrum of 7
shows a doublet at δ = 6.9 ppm allocated to the anomeric proton of the ribose moiety with J coupling constant equal to
4.25 Hz that matches the 1’-proton the β-configuration. With the appearance of aromatic group complex signals, a singlet
peak appeared at δ = 7.88 ppm allocated to the H-5, and another singlet signal at δ = 6.94 ppm assigned to the H-8. The 1H
NMR of 7 showed the predicted base moiety protons in addition to the sugar moiety protons. Calculated 1H, and 13C NMR
of an optimized molecular geometry of compound 7 in deuterated methanol solvent are provided for comparison (Figure
1; experimental section). Compound 7 was confirmed using mass spectra which showed a molecular ion peak ion (M+) at
m/z = 327.21 (2.77%), (calc. 328.27) for molecular formula C14H14F2N2O5, the base peak = 319.18 (100).
3.1. DFT theoretical calculations
3.1.1. Molecular geometry
The optimal molecular structures were predicted using DFT calculations at the B3LYP 6311G (d, p) basis set to assess
the stability of the expected positional isomers. To estimate the most stable positional isomer of the produced compound
3, calculations were performed for the proposed two isomers, 3a and 3b. These computations entailed doing a geometry
structure optimization on each isomer to obtain the least energy structure, then calculating the frequency at the optimized
geometry. In addition, several thermochemical parameters were calculated (Figure 2; Table 2). Free energy (G) and
enthalpy (H) were calculated to determine the relative stabilities, corrected energy, and thermodynamic parameters of
both positional isomers of compound 3.
The DFT calculations revealed that the 3b isomer had the lowest energy structure and the most stability in comparing
both geometrical isomers. The 3b isomer, on the other hand, is the least stable. The energy difference between both isomers
is 11.2 kcal/mol. However, the amid derivative 3b higher stability could be illustrated in its tautomeric ability with the
conjugated C=O group (Figure 3).
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Scheme 3. Synthesis of nucleoside 6,7-difluoro-2-methyl-4-quinazolinone.

Figure 1. Calculated 1H, and 13C NMR of an optimized molecular geometry of compound 7

13
in deuterated
solvent. MEP1H
graphand
is also presented.
Figure
1.methanol
Calculated
C NMR of an optimized
molecular geometry of compound 7 in deuterated methanol
solvent. MEP graph is also presented.

Figure 2. Calculated optimized molecular geometry of both isomers of compound 3.
Figure 2. Calculated optimized molecular geometry of both isomers of compound 3.
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Table 2. Thermal parameters (hartree/particle) of both positional isomers of compound 3.
Parameter

3a

3b

Ecorr

0.139237

0.139796

ZPVE

–730.840481

–730.858147

Etot

–730.829206

–730.847069

H

–730.828262

–730.846124

G

–730.878053

–730.895234

ΔE in kcal/mol

11.209

0.00

OH

O
F
F

N

F

H

N

F

N

N

Figure
Tautomeric
isomerism
of compound
3.
Figure 3.3.
Tautomeric
isomerism
of compound
3.
On the other hand, the intermolecular H-bonding could affect the stability of the predicted stable isomer 3b. Isomer
3b can form intermolecular H-bonding with two strong H-bonds than the other isomer 3a. The formation of two H-bonds
will enhance the stability of the amid isomer 3b more than the other isomer (Figure 4).
3.2. Docking analysis
This docking study investigates how a nucleoside ligand might interact in the active site of the main protease (Mpro; PDB
code 7BQY, 1EVE) for Alzheimer’s disease and COVID-19 [15]. Hydrogen bonding, hydrophobic interactions, and
other factors, e.g., entropy and solvation, can control the structural reorganization of both the ligand and the receptor
upon binding. It remains challenging to predict the conformational changes of 7BQY, 1EVE, and the ligand, as both are
expected to display different degrees of adjustment after binding [33]. The docked molecule in 7BQY is shown in Figure
5. The confirmation of all molecules has been demonstrated with respect to the known medicine Remdesivir Figure 5.
It has been noticed that the Met165(A), Arg188(A), Gln189(A), and Gly143(A) amino acids are the common residues,
forming hydrophobic interactions among all the compounds used in this study. At the same time, Remdesivir forms
four hydrogen bonds (Leu141(A), Asn143(A), Ser144(A) and Glu166(A)). Similarly, compound 7 also forms 4 hydrogen
bonds ((Leu141(A), Ser144(A), His163(A) and Glu166(A)). N3 displays three hydrogen bonds (Leu41(A), Asn142(A)
and His163(A)). Compounds 3a and 3b show one and two hydrogen bonds, respectively, Figures 6 and 7. A superposition
of compounds 3a, 3b, 7, remdesivir drug, and N3 inhibitor docked into the binding pocket of 7BQY using the identical
parameters for a fair comparison. The outcomes are presented in Figure 5. The number and type of interactions between
the remdesivir, N3, 7, 3a, 3b and the main protease (7BQY) are summarized in Figure 6 and partly in Figure 7. The
laydown of all docked ligands is presented together (with and without 7BQY), showing their fitting in the same active
site but different positioning (Figure 5). Also, the display of the superposition of each ligand compared to remdesivir is
displayed for easy comparison. This is represented by PyMOL by Schrödinger [56].
N
H

N

F

F
O

O
F

F

N

H

N

Figure 4. Intermolecular
H-bonding of amid isomer 3b.
Figure 4. Intermolecular H-bonding
of amid isomer 3b.
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Figure
5. The superposition
of compounds3a,
3a, 3b,
3b, 7,7,Remdesivir
drug,
and N3
Figure 5. The
superposition
of compounds
remdesivir
drug,
andinhibitor
N3 inhibitor
into the binding
of 7BQY
identicalparameters
parameters for
comparison
docked intodocked
the binding
pocketpocket
of 7BQY
usingusing
thethe
identical
fora fair
a fair
comparison
(circled,
middle window).
bottom window).
For clarity,
all dockedligands
ligands are
are shown
in in
thethe
top top
central
(circled, middle
bottom
For
clarity,
all
docked
shown
central
window without the 7BQY,
Mpro. Finally, the display of each
pro
window without the 7BQY, M . Finally, the display of each ligand after docking is compared to
remdesivir (orange in color). This is represented by PyMOL by Schrödinger (downloaded from
https://pymol.org/2/) [56].

Figure 6.Figure
Number
and type
interactions
between
the remdesivir,
N3, 7,N3,
3a,7,3b,
6. Number
andoftype
of interactions
between
the Remdesivir,
3a,and
3b,the
andmain
the
proteasemain
(7BQY).
protease (7BQY).
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a

b

7. (a)
schematic 2D2D
LIGPLOT
illustration
of Remdesivir
the main protease
FigureFigure
7. (a)
AAschematic
LIGPLOT
illustration
of and
remdesivir
and the main
7BQY. The purple stick at the center represents Remdesivir, whereas the remaining are the
protease
7BQY.
The
purple
stick
at
the
center
represents
remdesivir,
whereas
amino acids residues. The green dashes are the hydrogen bond, and the thin red dashes and
the remaining
arepointing
the amino
acids
residues.
The green dashes are the hydrogen
the spoked arcs
towards the
ligand
represent the
bond, and the thin red dashes and the spoked arcs pointing towards the ligand
represent the hydrophobic residue bonds with remdesivir. The active site residues:
Leu141(A), Asn143(A), Ser144(A), and Glu166(A) are involved in making
a hydrogen bond with the ligand. Atoms marked by spokes in the ligand or
protein are involved in the interactions without the red lines. (b) A schematic 2D
LIGPLOT illustration of compounds 7 and 7BQY represented by PyMOL [56].

3.3. Binding prediction of compound 7 compared to donepezil using molecular docking
Docking analysis of compound 7 and donepezil was carried out on the Torpedo California acetylcholinesterase to study
their binding affinity (TcAChE) (PDB, 1EVE), [57–62]. Compound 7 demonstrated a close-fitting binding against the
TcAChE enzyme with close binding energy of –9.7 kcal/mol compared to donepezil (–10.9 kcal/mol) (Figures 8 and 9).
The molecular structure of 7 and donepezil after binding with the protein are shown in Figures 8 and 9. Compound 7
shows conventional hydrogen bonds, fluorine-hydrogen bonds, carbon-hydrogen bonds, and van der Waals interaction.
In contrast, the donepezil drug does not exhibit any of these interactions, indicating probably considerable flexibility of
compound 7 that facilitates the tight interaction with the binding site for the quaternary nitrogen of AChE enzyme [33].
Donepezil drug demonstrates mainly p-s and p-p stacked interactions (Figure 9). Superimposition of 7 (blue line) and
donepezil (orange line) is shown in Figure 8, which demonstrates the benzylpiperidine group oriented towards PHE, TYR,
and TRP residues. Similarly, the quinazoline moiety in compound 7 is directed towards PHE, TYR, and TRP residues. The
inden-1-one group of donepezil oriented towards TRP, ARG, and LEU residues (Figure 9), whereas the hydrofuran moiety
in 7 is directed towards SER, TYR, and Val residues. TRP84 interacts via π-sigma interaction with a distance of 3.37 Å. In
contrast, in the case of donepezil, it exhibits a π - π stacking with a distance of 4 Å (Figure 9). Three conventional hydrogen
bonds were found between the hydroxyl groups and SER81, TYR70, and TYR121 residues with distances of 3.3, 3.72,
and 5.95 Å, respectively (Figure 9). Interestingly, as can be seen, at the bottom of the gorge, a C=O···HIS440 hydrophobic
interaction was formed in the active site of AChE [63]. This interaction was not detected in the donepezil drug case. This
might enhance the affinity to the enzyme and therefore improve the inhibition effect of compound 7.
3.4. Toxicity prediction (in silico) for our ligands in comparison to remdesivir and N3
ProTox-II virtual lab was used to predict the toxicity of our small molecules in comparison to the authorized drug
remdesivir [64-70] and N3 inhibitor [31]. The oral toxicity presented as lethal dose (LD) at 50% (LD50) milligrams per
kilograms weight of the test population. ProTox-II predicted the toxicity classes as class 3 for 3a and 3b and LD50 of 200
mg/kg with the same average similarity and prediction accuracy of 60.65% and 68.07%, respectively (Table 3). Interestingly,
the toxic activity of 7 is predicted as class 4, which is similar to the approved drug, remdesivir, with LD50 of 1000 mg/kg.
The average similarity and prediction accuracy of 7 and remdesivir were 66.03%, 68.07%, and 40.93%, 54.26%, respectively
(Table 3). Compound N3 was predicted as the lowest toxic compound in this study as class 5 with LD50 of 4000 mg/kg and
average similarity and prediction accuracy of 45.06% and 54.26, respectively (Table 3).
The ProTox-II web server can also predict organ toxicity. For example, the hepatoxicity estimation of the three ligands
3a, 3b, the approved medicine for COVID-19 remdesivir and N3 inhibitor were all not active. In contrast, 7 was predicted
as a functional ligand on organ toxicity (Lever) with a probability of 0.52. Predicted activities for all studied ligands and the
controls (remdesivir and N3) were inactive (noncarcinogenic, non immunotoxin, nonmutagenic, noncytotoxic) (Table 4).
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Figure 10 depicts the prediction of the FMOs energy levels and their energy gap of 3a and 3b and its nucleoside 7.
The energy levels of the FMOs in compound 3a are lower than those in compound 3b, which could be explained in terms
of conjugation. The presence of an H-atom adjacent to the C=O group enhances the tautomerism with the OH. It may
decrease the conjugation of the C=O group with the ring, inhibiting the conjugation with the benzene ring. This effect on
MO levels has an impact on the chemical descriptors that are used to illustrate the biological activity of these compounds.
However, the attachment of the hydrophilic carbohydrate moiety of the isomer 3a affects the energy difference between
the orbitals with a small value ΔE = 4.74 e.V. Also, it is evident that the isomerism highly affects the level of the LUMO
than the HOMO. Isomer 3b shows the lowest-lying LUMO. The low-lying LUMO orbital of 3b could predict its ability to
accept the electron than its tautomer and its nucleoside derivative 7. However, the higher topological, polar surface area,
lower hydrophobicity, in silico absorption and high H-bonding acceptor percent of compound 7 could illustrate its high
predicted biological activity against the inhibition of COVID 19 and Alzheimer infections.
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Table 3. Acute oral toxicity predicted by ProTox-II web server for ligands 3a, 3b, 7, remdesivir, and N3.
Ligands drug
and N3

Oral toxicity prediction results
Predicted LD50 (mg/kg)

Predicted toxicity class

Average similarity (%)

Prediction accuracy (%)

3a

200

3

60.65

68.07

3b

200

3

60.65

68.07

7

1000

4

66.03

68.07

Remdesivir

1000

4

40.93

54.26

N3

4000

5

45.06

54.26

Table 4. Organ toxicity and toxicological endpoints predicted activity calculated using the ProTox-II web server for ligands 3a, 3b, 7,
remdesivir, and N3.
Ligands drug
and N3

Hepatotoxicity

Carcinogenicity

Immunotoxicity

Mutagenicity

Cytotoxicity

Activity Probability Activity Probability Activity

Probability

Activity Probability Activity Probability

3a

x

0.54

x

0.51

x

0.99

x

0.64

x

0.90

3b

x

0.54

x

0.51

x

0.97

x

0.64

x

0.90

7

√

0.52

x

0.66

x

0.96

x

0.77

x

0.77

Remdesivir

x

0.56

x

0.55

x

0.90

x

0.62

x

0.55

N3

x

0.58

x

0.52

x

0.96

x

0.61

x

0.67

Figure 10. Molecular orbital distribution and localization for FMOs of 3a, 3b,
and 7.

4. Conclusions
Synthesis of some of the ribosylation of silated compound 4 with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose
5 gave β-anomeric of the benzoylated nucleoside derivatives 6. Deprotection of the latter using dry absolute methanol
and sodium metal gave the new free N-nucleosides 7, in moderate yields. The new compounds obtained have been
characterized by their spectral analysis. The prediction analysis using the Pro Tox -II server showed that compound 7
has a similar feature to the approved antiviral drug remdesivir for COVID-19. Compound 7 behaved similarly in all tests
except on hepatotoxicity. This suggests that compound 7 may be worth additional study in the context of a possible drug
for COVID-19. A molecular modeling investigation confirmed, in silco, that our nucleosides 7 is an excellent binding
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inhibition of AChE enzyme. Compound 7 could be a possible effective drug against Alzheimer’s disease. Finally, DFT
was used to demonstrate molecular geometry and the thermodynamic parameters that could be used to illustrate the
MD results in terms of the structural activity correlation computed from FMOs using molecular descriptors. Compound
7 demonstrated its predicted activity towards binding inhibition of AChE enzyme and Alzheimer’s disease due to higher
hydrophilicity, a larger topological polar surface area, and a strong H-bonding acceptor.
Funding
This research was funded by Researchers Supporting project Taif, Kingdom of Saudi Arabia (KSA, grant number
TURSP-2020/137).
Acknowledgments
The authors thank Taif University, Taif University Researchers Supporting project number (TURSP-2020/137), Taif
University, Taif, Kingdom of Saudi Arabia (KSA). MAS is thankful to the Alexander von Humboldt Foundation for its
continuous support.
Conflict of interest
The authors declare no conflicts of interest. The funders had no role in the design of the study, in the collection, analyses,
or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
References
1.

Santagati NA, Bousquet E, Spadaro A, Ronsisvalle G. 4-Quinazolinones: Synthesis and reduction of prostaglandin E2 production. Farmaco
1999; 54: 780–784. doi: 10.1016/S0014-827X(99)00102-0

2.

Zayed MF, Ahmed HEA, Ihmaid S, Omar ASM, Abdelrahim AS. Synthesis and screening of somenew fluorinated quinazolinonesulphonamide hybrids as anticancer agents. Journal of Taibah University Medical Sciences 2015; 10: 333–339. doi: 10.1016/j.
jtumed.2015.02.007

3.

Singhal TA Review of Coronavirus Disease-2019 (COVID-19). Indian Journal of Pediatrics 2020; 87: 281–286. doi: 10.1007/S12098-02003263-6

4.

Radwan AA, Alanazi FK. Biological Activity of Quinazolinones, IntechOpen 2020. DOI: 10.5772/intechopen.90621

5.

Poorirani S, Sadeghian-Rizi S, Khodarahmi G, Khajouei M, Hassanzadeh F. Synthesis and cytotoxic evaluation of novel quinazolinone
derivatives as potential anticancer agents. Research in Pharmaceutical Sciences 2018; 13: 450. doi:10.4103/1735-5362.236838

6.

Gawad N, Georgey H, Youssef R, El-Sayed N. Synthesis and antitumor activity of some 2, 3-disubstituted quinazolin-4 (3H)-ones and
4,6-disubstituted-1, 2,3,4-tetrahydroquinazolin-2H-ones. European Journal of Medicinal Chemistry 2010; 45: 6058–6067.

7.

Andreeva OV, Belenok MG, Saifina LF, Shulaeva MM, Dobrynin AB et al. Synthesis of novel 1,2,3-triazolyl nucleoside analogues bearing
uracil, 6-methyluracil, 3,6-dimethyluracil, thymine, and quinazoline-2,4-dione moieties. Tetrahedron Letters 2019; 60.

8.

Abdel Gawad NM, Georgey HH, Youssef RM, El-Sayed NA. Synthesis and antitumor activity of some 2, 3-disubstituted quinazolin-4(3H)ones and 4,6-disubstituted- 1,2,3,4-tetrahydroquinazolin- 2H-ones. European Journal of Medicinal Chemistry 2010; 45: 6058–6067.
doi:10.1016/j.ejmech.2010.10.008

9.

Rajput C, Singhal S. Synthesis, characterization, and antiinflammatory activity of newer quinazolinone analogs, Downloads.Hindawi.
Com 2013. Journal of pharmaceutics 2013; 2013: 1–7. doi:10.1155/2013/907525

10.

Gatadi S, Lakshmi TV, Nanduri S. 4(3H)-Quinazolinone derivatives: Promising antibacterial drug leads. European Journal of Medicinal
Chemistry 2019; 170: 157–172. doi:10.1016/J.EJMECH.2019.03.018

11.

Sharaf A, Ragab S, Elbarbary A, Elkhabiry S. Synthesis and biological evaluation of some 3H-quinazolin-4-one derivatives. Springer 2021;
doi:10.1007/s13738-021-02315-8

12.

Zhang J, Liu J, Ma Y, Ren D, Cheng P et al. One-pot synthesis and antifungal activity against plant pathogens of quinazolinone derivatives
containing an amide moiety. Bioorganic Medicinal Chemistry Letters 2016; 26: 2273–2277. doi:10.1016/J.BMCL.2016.03.052

13.

Asif M. Chemical Characteristics, Synthetic Methods, and Biological Potential of Quinazoline and Quinazolinone Derivatives.
International Journal of Medicinal Chemistry 2014; 2014: 1–27. doi:10.1155/2014/395637

14.

Demeunynck M, Baussanne I. Survey of Recent Literature Related to the Biologically Active 4(3H)-Quinazolinones Containing Fused
Heterocycles. Current Medicinal Chemistry 2013; 20: 794–814. doi:10.2174/0929867311320060006

1837

BREAK et al. / Turk J Chem
15.

Zahlenreilien L, Lage D, I. Ueber. Beitrage zur Kenntniss. Journal Für Praktische. Chemie 1887; 141–154 (in German).

16.

Foucourt A, Hédou D, Dubouilh-Benard C, Girard A, Taverne T et al. Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A
Inhibitors, Part I. Molecules 2014;19: 15546–15571.

17.

Foucourt A, Hédou D, Dubouilh-Benard C, Girard A, Taverne T et al. Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A
inhibitors, Part II, Molecules 2014; 19: 15411–15439. doi:10.3390/molecules191015411

18.

Couly F, Diharce J, Bonnet P, Meijer L, Fruit C, Besson T. Conception of DYRK1A kinase inhibitors via metal-catalyzed C–H arylation,
inspired by fragment-growing studies, in 4th International Electronic Conference on Medicinal Chemistry 2018; p. 5580. doi:10.3390/
ecmc-4-05580

19.

Shah P, Westwell AD. The role of fluorine in medicinal chemistry. Journal of Enzyme Inhibition and Medicinal Chemistry 2007; 22;
527–540. doi:10.1080/14756360701425014

20.

Ghorab MM, Abdel-Gawad SM, El-Gaby MSA. Synthesis and evaluation of some new fluorinated hydroquinazoline derivatives as
antifungal agents. Farmaco 2000; 55: 249–255. doi:10.1016/S0014-827X(00)00029-X

21.

Layeva AA, Nosova EV, Lipunova GN, Trashakhova TV, CharushinVN. A new approach to fluorinated 4(3H)-quinazolinones. Journal of
Fluorine Chemistry 2007; 128: 748–754. doi:10.1016/j.jfluchem.2007.03.005

22.

Akher FB, Farrokhzadeh A, Ravenscroft N, Kuttel MM. Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a
Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the
Inhibitory Activity. Journal of Physical Chemistry B 2020; 124: 5813–5824. doi:10.1021/ACS.JPCB.0C03440

23.

Break LM, Alharthi W. Synthesis new of nucleoside of 1, 3-bis-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-8-(trifluoromethyl)-2-methyl-4quinazolinone. Proceedings 2018; 9: 57. doi:10.3390/ecsoc-22-05694

24.

Break LM. Synthesis of 8-Trifluloromethyl-2-Thioquinazolin-(3H)-4-One Nucleosides, International Journal Chemistry 2017; 9: 82.
doi:10.5539/ijc.v9n4p82

25.

Break LM. Synthesis and Characterization of New 8-trifluloromethyl Quinazolin-2,4-(3H)-Dione Nucleosides International Journal
Chemistry 2017; 9: 73. doi:10.5539/ijc.v9n1p73

26.

Break LM. Synthesis of Some of Fluorinated Benzimidazole Nucleosides. International Journal Chemistry 2016; 8: 188. doi:10.5539/ijc.
v8n1p188

27.

Ouahrouch A, Taourirte M, Engels JW, Benjelloun S, Lazrek HB. Synthesis of new 1,2,3-triazol-4-yl-quinazoline nucleoside and
acyclonucleoside analogues. Molecules 2014; 19: 3638–3653. doi:10.3390/molecules19033638

28.

Qiu J, Chen W, Zhang Y, Zhou Q, Chen J et al. Assessment ofquinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors.
European Journal of Medicinal Chemistry 2019; 176: 41–49. doi:10.1016/J.EJMECH.2019.05.014

29.

Laeva AA, Nosova EV, Lipunova GN, Golovchenko AV, Adonin NY et al. Fluorine-containing heterocycles: XIX. synthesis of fluorinecontaining quinazolin-4-ones from 3,1-benzoxazin-4-ones. Russian Journal of Organic Chemistry 2009; 45: 913–920. doi:10.1134/
S1070428009060190

30.

Vorbrüggen H, Krolikiewicz K, Bennua B. Nucleoside syntheses, XXII Nucleoside synthesis with trimethylsilyl triflate and perchlorate as
catalysts. Chemische Berichte 1981; 114: 1234–1255. doi:10.1002/cber.19811140404

31.

Jin Z, Du X, Xu Y, Deng Y, Liu M et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020; 582: 289–293.
doi:10.1038/s41586-020-2223-y

32.

Dhama K, Sharun K, Tiwari R, Dadar M, Singh Malik Y et al.COVID-19, an emerging coronavirus infection: advances and prospects in
designing and developing vaccines, immunotherapeutics, and therapeutics. HumanVaccines & Immunotherapeutics 2020; 16: 1232–1238.
doi:10.1080/21645515.2020.1735227

33.

Alsafi MA, Hughes DL, Said MA. First COVID-19 molecular docking with a chalcone-based compound: Synthesis, single-crystal
structure and Hirshfeld surface analysis study. Acta Crystallographics Secttion: C Structural Chemistry 2020; 76: 1043–1050. doi:10.1107/
S2053229620014217

34.

Fan X, Zhang X, Zhou L, Keith KA, Kern ER et al. A pyrimidine-pyrazolone nucleoside chimera with potent in vitro anti-orthopoxvirus
activity. Bioorganic & Medicinal Chemistry Letters 2006; 16: 3224–3228. doi:10.1016/j.bmcl.2006.03.043

35.

Wang CX, Zhang ZL, Yin QK, Tu JL, Wang JE et al. Design, Synthesis, and Evaluation of New Quinazolinone Derivatives that Inhibit
Bloom Syndrome Protein (BLM) Helicase, Trigger DNA Damage at the Telomere Region, and Synergize with PARP Inhibitors. Journal
Medicinal Chemistry 2020; 63: 9752–9772. doi:10.1021/ACS.JMEDCHEM.0C00917/SUPPL_FILE/JM0C00917_SI_002.CSV

36.

Allouche A, Khodair AI, El-Barbary AA, Imam DR, Kheder NA et al. Software News and Updates Gabedit — A Graphical user interface
for computational Chemistry softwares. Journal of Computational Chemistry 2012; 32: 174–182. doi:10.1002/jcc

1838

BREAK et al. / Turk J Chem
37.

Wallace AC, Laskowski RA, Thornton JM. Ligplot: A program to generate schematic diagrams of protein-ligand interactions. Protein
Engineering Design and Selection 1995; 8: 127–134. doi:10.1093/protein/8.2.127

38.

Al-Otaibi JS, Sheena Mary Y, Shyma Mary Y, Panicker CY, Thomas R. Cocrystals of pyrazinamide with p-toluenesulfonic and
ferulic acids: DFT investigations and molecular docking studies. Journal Molecular Structure 2019; 1175: 916–926. doi:10.1016/J.
MOLSTRUC.2018.08.055

39.

Hagar M, Ahmed HA, Aljohani G, Alhaddad OA. Investigation of some antiviral N-heterocycles as COVID 19 drug: Molecular docking
and DFT calculations. International Journal of Molecular Sciences 2020; 21: 3922. doi:10.3390/ijms21113922

40.

Pap C, Mohapatra RK, El-ajaily MM, Alassbaly FS, Sarangi AK et al. DFT, anticancer, antioxidant and molecular docking investigations of
some ternary Ni (II) complexes with 2- phenol. Springer 2021; 75: 1005–1019. doi:10.1007/s11696-020-01342-8

41.

Bouachrine M, Hamidi M, Bouzzine SM, Taoufik H. Theoritical study on the structure and electronic properties of new materials
based on thiophene and oxadiazole. Journal of Applied Chemical Research 2009; 10: 29–37. https://www.sid.ir/en/Journal/ViewPaper.
aspx?ID=195555

42.

Yang L, Feng JK, Liao Y, A.M. Ren QM. Theoretical studies on the electronic and optical properties of two blue-emitting fluorene-pyridinebased copolymers. Optical Materials 2007; 29: 642–650. doi:10.1016/j.optmat.2005.11.024

43.

Alnoman RB, Parveen S, Hagar M, Ahmed HA, Knight JG. A new chiral boron-dipyrromethene (BODIPY)-based fluorescent probe:
molecular docking, DFT, antibacterial and antioxidant approaches. Journal. Biomolecular Structure and Dynamis 2020; 38: 5429–5442.
doi:10.1080/07391102.2019.1701555.

44.

Alnoman RB, Hagar M, Parveen S, Ahmed HA, Knight JG. Computational and molecular docking approaches of a New axially chiral BODIPY
fluorescent dye. Journal of Photochemistry and Photobiology A: Chemistry 2020; 395: 112508. doi:10.1016/j.jphotochem.2020.112508

45.

Joshi R, Pandey N, Yadav SK, Tilak R, Mishra H et al. Synthesis, spectroscopic characterization, DFT studies and antifungal activity
of (E)-4-amino-5-[N’-(2-nitro-benzylidene)-hydrazino]-2,4-dihydro-[1,2,4]triazole-3-thione. Journal Molecular Structure 2018; 1164:
386–403. doi:10.1016/j.molstruc.2018.03.081

46.

Joshi R, Kumari A, Singh K, Mishra H, Pokharia S. Triorganotin(IV) complexes of Schiff base derived from 1,2,4-triazole moiety:
Synthesis, spectroscopic investigation, DFT studies, antifungal activity and molecular docking studies. Journal Molecular Structure 2020;
1206: 127639. doi:10.1016/j.molstruc.2019.127639

47.

Khodair AI, Awad MK, Gesson JP, Elshaier YAM. New N-ribosides and N-mannosides of Rhodamine Derivatives for Suppressing
Leukemia Cell Line Growth. Journal Clinical Haematology 2020; 1: 7–9. doi:10.33696/haematology.1.002

48.

Suresh Kumar S, Athimoolam S, Sridhar B. Structural, spectral, theoretical and anticancer studies on new co-crystal of the drug
5-fluorouracil. Journal Molecular Structure 2018; 1173: 951–958. doi:10.1016/j.molstruc.2018.07.079

49.

Hagar M, Ahmed HA, El-Sayed TH, Alnoman R. Mesophase behavior and DFT conformational analysis of new symmetrical diester
chalcone liquid crystals. Journal of Molecular Liquids 2019; 285: 96–105. doi:10.1016/j.molliq.2019.04.083

50.

Grover M, Singh B, Bakshi M, Singh S. Quantitative structure-property relationships in pharmaceutical research - Part 2. Pharmaceutical
Science and Technology Today 2000; 3: 50–57. doi:10.1016/S1461-5347(99)00215-1

51.

Malhotra R, Ravesh A, SinghV. Synthesis, characterization, antimicrobial activities, and QSAR studies of organotin(IV) complexes,
Phosphorus, Sulfur and Silicon Related Elements 2017; 192; 73–80. doi:10.1080/10426507.2016.1225054

52.

Kumer A, Sarker Md. N, Paul S. The simulating study of HOMO, LUMO, thermophysical and quantitative structure of activity relationship
(QSAR) of some anticancer active ionic liquids. Eurasian Journal of Environmental Research 2019; 3: 1-10. https://dergipark.org.tr/en/
pub/ejere/478362

53.

Lewis DFV. Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate
binding, inhibition and induction of P450s. Inflammopharmacology 2003; 11: 43–73. doi:10.1163/156856003321547112

54.

Almehmadi MA, Aljuhani A, Alraqa SY, Ali I, Rezki N, Aouad MR, Hagar M. Design, synthesis, DNA binding, modeling, anticancer
studies and DFT calculations of Schiff bases tethering benzothiazole-1,2,3-triazole conjugates. Journal Molecular Structure 2021; 1225:
129148. doi:10.1016/j.molstruc.2020.129148

55.

Jiang JB, Hesson DP, Dusak BA, Dexter DL, Kang GJ et al.. Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new
class of antimitotic anticancer agents which inhibit tubulin polymerization. Jounral Medicinal Chemistry 1990; 33: 1721–1728. https://
pubs.acs.org/doi/pdf/10.1021/jm00168a029

56.

DeLano WL. PyMOL Reference Guide, Delano Sci. San Carlos, CA, US.2004; 1–68.

57.

Sulimov VB, Kutov DC, Taschilova AS, Ilin IS, Tyrtyshnikov EE, Sulimov AV. Docking Paradigm in Drug Design. Current Topics in
Medicinal Chemistry 2021; 21 (6): 507-546. doi: 10.2174/1568026620666201207095626

1839

BREAK et al. / Turk J Chem
58.

Pant S, Singh M, Ravichandiran V, Murty USN. Hemant Kumar Srivastava H K. Peptide-like and small-molecule inhibitors against
Covid-19. Journal of Biomolecular Structure and Dynamics 2021; May 39 (8): 2904-2913. doi: 10.1080/07391102.2020.1757510

59.

Sonmez F, Kurt BZ, Gazioglu I, Basile L, Dag A, Cappello V, Ginex T, Kucukislamoglu M, Sonmez F, Kurt BZ, Gazioglu I, Basile L,
Cappello V, Ginex T, Kucukislamoglu M, Guccione S. Design , synthesis and docking study of novel coumarin ligands as potential selective
acetylcholinesterase inhibitors. Journal Enzyme Inhibition and Medicinal Chemistry 2017; 32(1): 285-297. doi:10.1080/14756366.2016.1
250753

60.

Karakaya S, Koca M, Volkan Yılmaz S, Yıldırım K, Pınar NM et al. Molecular docking studies of coumarins isolated from extracts
and essential oils of zosima absinthifolia link as potential inhibitors for alzheimer’s disease. Molecules 2019; 24: 722. doi:10.3390/
molecules24040722.

61.

Bajda M, Wiȩckowska A, Hebda M, Guzior N, Sotriffer CA et al. Structure-based search for new inhibitors of cholinesterases. International
Journal of Molecular Sciences 2013; 14: 5608–5632. doi:10.3390/ijms14035608

62.

Qin J, Lan W, Liu Z, Huang J, Tang H et al. Synthesis and biological evaluation of 1, 3-dihydroxyxanthone mannich base derivatives
as anticholinesterase agents. Chemistry Central Journal 2013; 7: https://www.sciencedirect.com/science/article/pii/S0022286020314708
(accessed November 25, 2021).

63.

Brown AD, Clegg MT, Kahler AL, Weir BS, Chang TT et al. Policy Statement on Cooperative Research and Development Agreements and
Intellectual Property Licensing, Sci. Technol 1990; 167: 2264.
Peele KA, Potla Durthi C, Srihansa T, Krupanidhi S, Ayyagari VS
et al. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. Informatics in
Medicine Unlocked 2020; 19: 100345. doi:10.1016/j.imu.2020.100345

65.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M et al. Emerging treatment strategies for COVID-19
infection. Clinical and Experimental Medicine 2021; 21 (2): 167-179. doi: 10.1007/s10238-020-00671-y

66.

Rosenberg K. Remdesivir in The Treatment of COVID-19. American Journal of Nursing 2021; Jan 1, 121(1): 55. doi: 10.1097/01.
NAJ.0000731668.01845.8c

67.

Yousefi H, Mashouri L, Okpechi SC, Alahari N, Alahari SK. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2
infection: A review describing drug mechanisms of action. Biochemical Pharmacology 2021; 183: 114296.doi: 10.1016/j.bcp.2020.114296

68.

Mhatre S, Naik Sh, Patravale V. A molecular docking study of EGCG and theaflavin digallate with the druggable targets of SARS-CoV-2.
Computers in Biology and Medicine 2021; Feb129: 104137. doi: 10.1016/j.compbiomed.2020.104137.

69.

Crampon K, Giorkallos A, Deldossi M. Stéphanie Baud, Luiz Angelo Steffenel, Machine-learning methods for ligand-protein molecular
docking. Drug Discovery Today 2022; Jan 27 (1):

151-164. doi: 10.1016/j.drudis.2021.09.007
70.

Talluri S. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19. Combinatorial Chemistry & High
Throughput Screening 2021; 24 (5): 716-728. doi: 10.2174/1386207323666200814132149

1840

